皮膚科治療薬市場：治療クラス別、投与経路別、適応症別、エンドユーザー別、流通チャネル別-2025-2030年の世界予測

皮膚科治療薬市場の2023年の市場規模は314億米ドルで、2024年には342億3,000万米ドルに達すると予測され、CAGR 9.83%で成長し、2030年には605億6,000万米ドルに達すると予測されています。

皮膚科治療薬の対象範囲には、にきび、乾癬、湿疹、皮膚感染症など、皮膚関連の問題を治療するために設計された幅広い治療製品が含まれます。皮膚科治療薬は、症状を緩和し、皮膚の健康を改善し、患者の自信を高める上で重要な役割を果たしています。最終用途には主に病院、皮膚科クリニック、薬局、個人消費者が含まれます。この市場を牽引しているのは、皮膚疾患に対する意識の高まり、医薬製剤の進歩、低侵襲治療に対する需要の高まりです。遠隔皮膚科学や個別化医療アプローチの増加、皮膚疾患を経験する高齢者人口の拡大により、新たなビジネスチャンスが見込まれています。バイオテクノロジー企業との戦略的提携や、デジタル・プラットフォームを活用したアウトリーチは、有利な成長機会をもたらす可能性があります。

しかし、市場は厳しい規制プロセス、高い研究開発コスト、皮膚科治療薬に関連する潜在的な副作用など、いくつかの課題に直面しています。また、新興国市場でのアクセシビリティの低さや、ジェネリック医薬品との競合も市場拡大の大きな障壁となっています。バイオ医薬品、ドラッグデリバリーシステムにおけるナノテクノロジー、オーガニック・ナチュラルベースの皮膚科製品の開発といった分野は、成長のための有望な道筋を提供するものです。皮膚状態の予測や薬効の最適化のためのAI主導型ソリューションの探求も、この分野に革命をもたらす可能性があります。皮膚科医薬品市場の性質は非常にダイナミックであり、急速な技術進歩や、より安全で効果的な治療法への消費者の嗜好の変化を特徴としています。この領域で優位性を確保しようとする企業は、包括的な研究開発を重視するとともに、ヘルスケアプロバイダーや規制機関との強力な提携関係を築く必要があります。進化する患者のニーズと規制状況に常に敏感であることが重要です。さらに、潜在的な市場シフトに先手を打って対処し、新たな動向や消費者の期待に機敏に対応するためには、データ分析を通じて詳細な市場洞察を得ることが必要となります。全体として、皮膚科治療薬市場における課題を克服し、成長の可能性を最大化するためには、イノベーションと結びついた患者中心のアプローチが最も重要です。

市場力学：急速に進化する皮膚科治療薬市場の主要市場インサイトを公開

皮膚科治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 乾癬、湿疹、にきび、皮膚がんなどの皮膚疾患の有病率の増加
  • 医薬品開発における技術的進歩、および皮膚科治療薬の強力なパイプライン
  • 高齢者の治療抵抗性疾患に対する生物学的製剤の採用増加
• 市場抑制要因
  • 厳しく時間のかかる規制当局の承認プロセス
• 市場機会
  • 個別化医療への投資の増加、遠隔医療への応用の高まり
  • 皮膚科学製品における天然成分やオーガニック成分への顕著なシフト
• 市場の課題
  • 高い治療費と厳しい規制政策

ポーターのファイブフォース：皮膚科治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：皮膚科治療薬市場における外部からの影響の把握

外部マクロ環境要因は、皮膚科治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析皮膚科治療薬市場における競合情勢の把握

皮膚科治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス皮膚科治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、皮膚科治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨皮膚科治療薬市場における成功への道筋を描く

皮膚科治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 乾癬、湿疹、ニキビ、皮膚がんなどの皮膚疾患の増加
    • 医薬品開発における技術的進歩と皮膚科用医薬品の強力なパイプライン
    • 高齢者疾患における治療抵抗性疾患に対する生物学的製剤の採用増加
  • 抑制要因
    • 厳格で時間のかかる規制承認プロセス
  • 機会
    • パーソナライズ医療への新たな投資と遠隔医療への応用の増加
    • 皮膚科製品における天然およびオーガニック成分への顕著な移行
  • 課題
    • 高額な治療費と厳しい規制政策
• 市場セグメンテーション分析
  • 治療クラス：重篤または難治性の皮膚疾患の治療のための皮膚科における免疫抑制剤の普及
  • エンドユーザー：外見と健康に対する社会の重視の高まりにより、美容クリニックや皮膚科クリニックへの関心が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 皮膚科治療薬市場治療クラス別

• 抗真菌薬
• コルチコステロイド
• 免疫抑制剤
• レチノイド

第7章 皮膚科治療薬市場：投与経路別

• オーラル
• 非経口注射
• 話題

第8章 皮膚科治療薬市場適応症の種類別

• ニキビ
• アトピー性皮膚炎
• 乾癬
• 皮膚がん

第9章 皮膚科治療薬市場：エンドユーザー別

• 美容・皮膚科クリニック
• 診断センターおよび検査室
• 病院

第10章 皮膚科治療薬市場：流通チャネル別

• 病院薬局
• 小売薬局

第11章 南北アメリカの皮膚科治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の皮膚科治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの皮膚科治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アルミラルとマイクロソフト、皮膚疾患の新たな治療法開発に向けた提携を発表
  • FDAが、脂漏性皮膚炎の治療として、Arcutis社のZORYVE（ロフルミラスト）外用フォーム0.3%を承認
  • イーライリリー、乾癬治療薬の発売で皮膚科分野に進出
• 戦略分析と提言

企業一覧

• Allergan plc by Abbvie Inc.
• Almirall S.A.
• Amgen Inc.
• Arcutis Biotherapeutics, Inc.
• Asterisk Laboratories
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Cipla Limited
• Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
• DermBiont, Inc.
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Galderma S.A.
• GlaxoSmithkline plc
• Johnson & Johnson Services, Inc.
• Leo Pharma A/S
• Lupin Ltd
• Mayne Pharma Group Ltd
• Merck & Co., Inc
• Novartis AG
• Pfizer Inc.
• Roivant Sciences Ltd.
• Shinom Cosmeceuticals

LIST OF FIGURES

• FIGURE 1. DERMATOLOGY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. DERMATOLOGY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DERMATOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DERMATOLOGY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PARENTERAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ACNE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AESTHETIC & DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Dermatology Drugs Market was valued at USD 31.40 billion in 2023, expected to reach USD 34.23 billion in 2024, and is projected to grow at a CAGR of 9.83%, to USD 60.56 billion by 2030.

The scope of dermatology drugs encompasses a wide range of therapeutic products designed to treat skin-related issues, including acne, psoriasis, eczema, and skin infections. Dermatology drugs play a crucial role in alleviating symptoms, improving skin health, and boosting patient confidence. The end-use scope primarily includes hospitals, dermatology clinics, pharmacies, and individual consumers. The market is driven by increasing awareness of skin conditions, advances in pharmaceutical formulations, and a growing demand for minimally invasive treatments. Emerging opportunities are anticipated due to the rise in teledermatology and personalized medicine approaches, as well as the expanding geriatric population experiencing skin ailments. Strategic partnerships with biotech firms and leveraging digital platforms for outreach can present lucrative growth opportunities.

However, the market confronts several challenges, such as stringent regulatory processes, high R&D costs, and the potential side effects associated with dermatology drugs. Limited accessibility in developing regions and heavy competition from generic drugs also pose significant barriers to market expansion. Innovation is key to overcoming these obstacles; areas like biopharmaceuticals, nanotechnology in drug delivery systems, and the development of organic and natural-based dermatology products offer promising avenues for growth. The exploration of AI-driven solutions for predicting skin conditions or optimizing drug efficacy could also revolutionize the sector. The nature of the dermatology drug market is highly dynamic, characterized by rapid technological advancements and a consumer preference shift towards safer, more effective treatments. Companies looking to assert dominance in this sphere must emphasize comprehensive research and development, alongside fostering strong alliances with healthcare providers and regulatory bodies. Remaining attuned to the evolving patient needs and regulatory landscapes will be critical. Additionally, gaining detailed market insights through data analytics will be necessary to preemptively address potential market shifts, ensuring agile adaptations to emerging trends and consumer expectations. Overall, a patient-centric approach, coupled with innovation, will be paramount in navigating the challenges and maximizing the growth potential within the dermatology drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dermatology Drugs Market

The Dermatology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
  • Technological advancements in drug development, along with a strong pipeline of dermatological drugs
  • Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
• Market Restraints
  • Stringent and time-consuming regulatory approval process
• Market Opportunities
  • Emerging investment in personalized medicine, and rising application in telemedicine
  • Notable shift towards natural and organic ingredients in dermatological products
• Market Challenges
  • High treatment costs and stringent regulatory policy

Porter's Five Forces: A Strategic Tool for Navigating the Dermatology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dermatology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dermatology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dermatology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dermatology Drugs Market

A detailed market share analysis in the Dermatology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dermatology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dermatology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dermatology Drugs Market

A strategic analysis of the Dermatology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dermatology Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc by Abbvie Inc., Almirall S.A., Amgen Inc., Arcutis Biotherapeutics, Inc., Asterisk Laboratories, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited, DermBiont, Inc., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., GlaxoSmithkline plc, Johnson & Johnson Services, Inc., Leo Pharma A/S, Lupin Ltd, Mayne Pharma Group Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc., Roivant Sciences Ltd., and Shinom Cosmeceuticals.

Market Segmentation & Coverage

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Class, market is studied across Antifungals, Corticosteroids, Immunosuppressants, and Retinoids.
• Based on Route of Administration, market is studied across Oral, Parenteral Injection, and Topical.
• Based on Indication Type, market is studied across Acne, Atopic dermatitis, Psoriasis, and Skin cancer.
• Based on End-User, market is studied across Aesthetic & Dermatology Clinics, Diagnostic Centers & Laboratories, and Hospitals.
• Based on Distribution Channel, market is studied across Hospital pharmacies and Retail pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
    • 5.1.1.2. Technological advancements in drug development, along with a strong pipeline of dermatological drugs
    • 5.1.1.3. Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent and time-consuming regulatory approval process
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging investment in personalized medicine, and rising application in telemedicine
    • 5.1.3.2. Notable shift towards natural and organic ingredients in dermatological products
  • 5.1.4. Challenges
    • 5.1.4.1. High treatment costs and stringent regulatory policy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapeutic Class: Proliferation of immunosuppressants in dermatology for the treatment of severe or refractory skin conditions
  • 5.2.2. End-User: High inclination towards aesthetic and dermatology clinics owing to increasing societal emphasis on appearance and wellness
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dermatology Drugs Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. Antifungals
• 6.3. Corticosteroids
• 6.4. Immunosuppressants
• 6.5. Retinoids

7. Dermatology Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral Injection
• 7.4. Topical

8. Dermatology Drugs Market, by Indication Type

• 8.1. Introduction
• 8.2. Acne
• 8.3. Atopic dermatitis
• 8.4. Psoriasis
• 8.5. Skin cancer

9. Dermatology Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Aesthetic & Dermatology Clinics
• 9.3. Diagnostic Centers & Laboratories
• 9.4. Hospitals

10. Dermatology Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital pharmacies
• 10.3. Retail pharmacies

11. Americas Dermatology Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Dermatology Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Dermatology Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Almirall and Microsoft announce partnership for the development of novel treatments for skin diseases
  • 14.3.2. FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis
  • 14.3.3. Eli Lilly forays into dermatological space with launch of psoriasis drug
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Allergan plc by Abbvie Inc.
• 2. Almirall S.A.
• 3. Amgen Inc.
• 4. Arcutis Biotherapeutics, Inc.
• 5. Asterisk Laboratories
• 6. AstraZeneca plc
• 7. Bayer AG
• 8. Bristol-Myers Squibb Company
• 9. Cipla Limited
• 10. Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
• 11. DermBiont, Inc.
• 12. Dr. Reddy's Laboratories
• 13. Eli Lilly and Company
• 14. F. Hoffmann-La Roche AG
• 15. Galderma S.A.
• 16. GlaxoSmithkline plc
• 17. Johnson & Johnson Services, Inc.
• 18. Leo Pharma A/S
• 19. Lupin Ltd
• 20. Mayne Pharma Group Ltd
• 21. Merck & Co., Inc
• 22. Novartis AG
• 23. Pfizer Inc.
• 24. Roivant Sciences Ltd.
• 25. Shinom Cosmeceuticals